

OTHERS

Phase I study of combined therapy with vorinostat and gefitinib to treat *BIM* deletion polymorphism-associated resistance in *EGFR*-mutant lung cancer (VICTROY-J) : a study protocol

Shinji Takeuchi¹, Kenichi Yoshimura², Tadami Fujiwara³, Masahiko Ando³, Shinobu Shimizu³, Katsuhiko Nagase², Yoshinori Hasegawa⁴, Toshiaki Takahashi⁵, Nobuyuki Katakami⁶, Akira Inoue⁷, and Seiji Yano^{1,2}

¹Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Ishikawa, Japan ; ²Innovative Clinical Research Center (iCREK), Kanazawa University Hospital, Ishikawa, Japan ; ³Center for Advanced Medicine and Clinical Research, Nagoya University Hospital, Aichi, Japan ; ⁴Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Aichi, Japan ; ⁵Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan ; ⁶Division of Integrated Oncology, Institute of Biomedical Research and Innovation ; ⁷Department of Palliative Medicine, Tohoku University School of Medicine.

Abstract : The *BIM* deletion polymorphism is reported to be associated with poor outcomes of epidermal growth factor receptor (*EGFR*)-mutant non-small cell lung cancer (NSCLC) treated with *EGFR*-TKIs, including gefitinib. We have shown that a histone deacetylase inhibitor, vorinostat, can epigenetically restore *BIM* function and apoptosis sensitivity to *EGFR*-TKIs in *EGFR*-mutant NSCLC cells with *BIM* deletion polymorphisms. The purpose of this study is to determine the feasibility of combined treatment of vorinostat with gefitinib in *BIM* deletion polymorphism positive *EGFR*-mutant NSCLC patients. *BIM* deletion polymorphism positive *EGFR*-mutant NSCLC patients treated with at least one *EGFR*-TKI and one regimen of chemotherapy are being recruited to this study. Vorinostat (200-400 mg) will be administered orally once daily on days 1-7, and gefitinib 250 mg orally once daily on days 1-14. With a fixed dose of gefitinib, the dose of vorinostat will be escalated following a conventional 3+3 design. The primary endpoint is to define the maximum tolerated dose (MTD) of vorinostat combined with 250 mg of gefitinib. This is the first phase I study of combined therapy with vorinostat and gefitinib for NSCLC patients double selected for an *EGFR* mutation and *BIM* deletion polymorphism. *J. Med. Invest.* 64 : 321-325, August, 2017

Keywords : *EGFR* mutation, *BIM* polymorphism, gefitinib, vorinostat, non-small cell lung cancer

INTRODUCTION

The majority of patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (*EGFR*) activating mutations, such as exon 19 deletion and L858R point mutation, show marked responses to *EGFR* tyrosine kinase inhibitors (*EGFR*-TKIs), such as gefitinib, erlotinib, and afatinib (1-4). However, 20-30% of patients with *EGFR*-activating mutations show intrinsic resistance to *EGFR*-TKIs. Molecular mechanisms of the intrinsic resistance are not fully understood (5).

BIM, also called Bcl-2-like protein 11, is a pro-apoptotic molecule that belongs to the Bcl-2 family. *BIM* upregulation is essential for the induction of apoptosis in lung cancer cells with *EGFR* mutations treated with first-generation *EGFR*-TKIs, and a low *BIM* protein level is associated with resistance to *EGFR*-TKIs (6, 7). Recently, an East Asian-specific 2,903 bp deletion polymorphism in the *BIM* gene was discovered, whose incidence was around 13% and 0.5% for heterozygous and homozygous carriers, respectively (8). Importantly, the *BIM* deletion polymorphism results in the preferential splicing of exon 3 over the BH3-encoding exon 4 in the *BIM* pre-mRNA, and leads to the production of inactive *BIM* isoforms lacking the BH3 domain. This in turn reduces expression of

pro-apoptotic *BIM* protein isoforms in *EGFR*-mutant lung cancer cell lines following TKI exposure and is sufficient to confer TKI resistance (8). Since its initial discovery, several meta-analyses have reported an association between *BIM* deletion polymorphism and shorter progression-free survival (PFS) of patients with NSCLC harboring *EGFR* mutations, who received gefitinib or erlotinib treatment (9-13).

Vorinostat (suberoylanilide hydroxamic acid [SAHA]), has been approved in 20 countries to date including Japan for cutaneous T-cell lymphoma as monotherapy, is a small-molecule inhibitor of histone deacetylase (HDAC) that induces cell differentiation, cell cycle arrest, and apoptosis in several types of tumor cell lines (14). We previously reported that the combined use of vorinostat and gefitinib was able to preferentially upregulate the expression of pro-apoptotic *BIM* isoforms in *EGFR*-mutant NSCLC cell lines with the *BIM* deletion polymorphism, and overcome *EGFR*-TKI resistance *in vitro* and *in vivo* (15). Two clinical trials, a phase I/II study combining gefitinib and vorinostat in patients with advanced NSCLC regardless of presence/absence of *EGFR* mutation in Korea (16) and a phase I/II study combining erlotinib and vorinostat with advanced *EGFR*-mutant NSCLC patients after *EGFR*-TKI progression in Spain (17) have been performed. However, the combination treatment did not show significant efficacy in these patient population and novel biomarker is warranted. Therefore, based on our preclinical findings, we designed the present phase I study named VICTROY-J “Vorinostat-Iressa Combined Therapy on Resistance by *BIM* Polymorphism in *EGFR* Mutant Lung Cancer” to evaluate the safety of combined therapy with vorinostat and gefitinib, and to

Received for publication March 2, 2017 ; accepted March 16, 2017.

Address correspondence and reprint requests to Seiji Yano, MD, PhD. Division of Medical Oncology Cancer Research Institute, Kanazawa University 13-1, Takaramachi, Kanazawa, Ishikawa, 920-0934, Japan and Fax : +81-76-244-2454.

determine the maximum tolerated dose (MTD) of vorinostat combined with a fixed dose of gefitinib for Japanese patients with *EGFR*-mutant NSCLC with a *BIM* deletion polymorphism.

METHODS AND DESIGN

Purpose

The primary objective is to determine the MTD of vorinostat combined with a fixed dose of gefitinib for patients with *EGFR*-mutant NSCLC with a *BIM* deletion polymorphism. The secondary objective is to evaluate the safety and efficacy of the combined therapy with vorinostat and gefitinib in the early-phase trial setting.

Study design

This study is an open-label, multi-institutional phase I dose-escalation study of participating institutions, include 5 specialized centers in Japan as of November 2016. Participating institutions are listed in Appendix 1.

Three to six patients will be enrolled at each dose level of vorinostat. With a fixed dose of gefitinib, dose escalation of vorinostat following a conventional 3+3 design using an escalation scheme will be used (Figure 1). Initially, 3 patients are enrolled to level 1. If one or two patients experience DLT, 3 additional patients are enrolled to the level. If 3 of 6 patients experience DLT, the previous level is declared the MTD. If 2 or less of 6 patients experience DLT, dose escalation is permitted to continue. After the termination of protocol treatment, any treatment is allowed.

Ethical considerations and registration

This study was conducted in accordance with the International Committee for Harmonization Good Clinical Practice (ICH-GCP) guideline and the Declaration of Helsinki. The study protocol was approved by the institutional review boards of all participating institutions. Informed consent will be provided for all patients

before registration. This study was registered with ClinicalTrials.gov (NCT02151721) and UMIN Clinical Trials Registry (UMIN 000015193).

Endpoint

The primary endpoint is MTD, which is defined as the highest dose level at which 2 or less of 6 patients experience a dose-limiting toxicity (DLT). Toxicities will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. DLT is defined as follows ; grade ≥ 1 intestinal lung disease ; grade ≥ 4 neutropenia lasting 5 days or more ; febrile neutropenia ; grade ≥ 3 thrombopenia requiring platelet transfusion ; grade ≥ 4 thrombopenia ; any grade uncontrollable skin toxicity ; grade ≥ 3 nonhematological toxicity. DLT will be evaluated during the first two cycles (14 days per cycle) of therapy.

The secondary endpoints are pharmacokinetics and pharmacodynamics of vorinostat and gefitinib, progression-free survival (PFS), overall survival (OS), response rate (RR), duration of response and complete response, disease control rate (DCR), and incidence of adverse events defined by Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.

Eligibility criteria

Inclusion criteria

Prior to enrollment in the study, patients must fulfill all of the following criteria : histologically or cytologically diagnosed NSCLC (excluding squamous cell carcinoma) ; NSCLC of clinicopathologic stage IIIB or IV for which radical radiation therapy is impractical or there is a recurrence after surgery ; *EGFR* mutations (deletion of exon 19 and L858R mutation of exon 21) for which the clinical benefits of an *EGFR*-TKI (gefitinib or erlotinib) are recognized by testing methods that are listed by the national health insurance ; having a history of treatment with an *EGFR*-TKI (gefitinib or erlotinib) and a history of pathologic deterioration during treatment ; having a history of treatment with cytotoxic anticancer agents (not including pre- or postoperative chemotherapy in the previous 1 or




Figure 1. Study design.

Dashed arrow ; if no DLTs are observed in all of 3 patients at lower dose level, additional 3 patients are recruited. DLTs, dose-limiting toxicities. MTD, maximum tolerated dose.

with gefitinib in Japanese *EGFR*-mutant NSCLC patients with *BIM* deletion polymorphism in this investigator-initiated trial, we would like to conduct phase II study in cooperation with pharmaceutical companies. If successful, this combined treatment with vorinostat and gefitinib may lead to substantial and important changes in the management of patients with *EGFR* mutant NSCLC with a *BIM* deletion polymorphism.

CONFLICT OF INTERESTS-DISCLOSURE

Yoshinori Hasegawa obtained speakers fees and research grant from AstraZeneca, Taiho, and MSD. Toshiaki Takahashi obtained speakers fees from AstraZeneca and Taiho and research grant from AstraZeneca, MSD, and Taiho. Nobuyuki Katakami obtained speakers fees and research grant from AstraZeneca and Taiho. Akira Inoue obtained speakers fees from AstraZeneca, Taiho and advisory fees from AstraZeneca and MSD. Seiji Yano obtained speakers fees and research grants from AstraZeneca and Taiho. The other authors have nothing to disclose.

GRANT SURPPORT

This study is supported by grants from the Japan Agency for Medical Research and Development, AMED, Grant Number 15Aak0101016h0003, 15Ack0106113h0002, and 16ck0106207h0001 (to SY) and Kanazawa University Hospital.

APPENDIX 1. Participating institutions

Participating institution	Principal investigator
1. Kanazawa University Hospital	Shinji Takeuchi
2. Nagoya University Hospital	Yoshinori Hasegawa
3. Institute of Biomedical Research and Innovati on Hospital	Nobuyuki Katakami
4. Tohoku University Hospital	Akira Inoue
5. Shizuoka Cancer Center	Toshiaki Takahashi

ACKNOWLEDGEMENTS

This study is supported by grants from the Japan Agency for Medical Research and Development, AMED, Grant Number 15Aak0101016h0003, 15Ack0106113h0002, and 16ck0106207h0001 (to SY) and Kanazawa University Hospital.

REFERENCE

- Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T ; North-East Japan Study Group : Gefitinib or chemotherapy for non-small-cell lung cancer with mutated *EGFR*. *N Engl J Med* 362 : 2380-2388, 2010
- Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M ; West Japan Oncology Group : Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405) : an open label, randomised phase 3 trial. *Lancet Oncol* 11 : 121-128, 2010
- Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L ; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica : Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced *EGFR* mutation-positive non-small-cell lung cancer (EURTAC) : a multicentre, open-label, randomised phase 3 trial. *Lancet Oncol* 13 : 239-246, 2012
- Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bannoun J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M : Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with *EGFR* mutations. *J Clin Oncol* 31 : 3327-3334, 2013
- Yano S, Takeuchi S, Nakagawa T, Yamada T : Ligand-triggered resistance to molecular targeted drugs in lung cancer : roles of HGF and *EGFR* ligands. *Cancer Sci* 103 : 1189-1194, 2012
- Faber AC, Corcoran RB, Ebi H, Sequist LV, Waltman BA, Chung E, Incio J, Digumarthy SR, Pollack SF, Song Y, Muzikansky A, Lifshits E, Roberge S, Coffman EJ, Benes CH, Gómez HL, Baselga J, Arteaga CL, Rivera MN, Dias-Santagata D, Jain RK, Engelman JA : *BIM* expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. *Cancer Discov* 1 : 352-365, 2011
- Costa C, Molina MA, Drozdowskyj A, Giménez-Capitán A, Bertran-Alamillo J, Karachaliou N, Gervais R, Massuti B, Wei J, Moran T, Majem M, Felip E, Carcereny E, Garcia-Campelo R, Viteri S, Taron M, Ono M, Giannikopoulos P, Bivona T, Rosell R : The impact of *EGFR*T790M mutations and *BIM* mRNA expression on outcome in patients with *EGFR*-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial. *Clin Cancer Res* 20 : 2001-2010, 2014
- Ng KP, Hillmer AM, Chuah CT, Juan WC, Ko TK, Teo AS, Ariyaratne PN, Takahashi N, Sawada K, Fei Y, Soh S, Lee WH, Huang JW, Allen JC Jr, Woo XY, Nagarajan N, Kumar V, Thalamuthu A, Poh WT, Ang AL, Mya HT, How GF, Yang LY, Koh LP, Chowbay B, Chang CT, Nadarajan VS, Chng WJ, Than H, Lim LC, Goh YT, Zhang S, Poh D, Tan P, Seet JE, Ang MK, Chau NM, Ng QS, Tan DS, Soda M, Isobe K, Nöthen MM, Wong TY, Shahab A, Ruan X, Cacheux-Rataboul V, Sung WK, Tan EH, Yatabe Y, Mano H, Soo RA, ChinTM, Lim WT, Ruan Y, Ong ST : A common *BIM* deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. *Nat Med* 18 : 521-528, 2012
- Ying HQ, Chen J, He BS, Pan YQ, Wang F, Deng QW, Sun HL, Liu X, Wang SK : The effect of *BIM* deletion polymorphism on intrinsic resistance and clinical outcome of cancer patient with kinase inhibitor therapy. *Sci Rep* 5 : 11348, 2015
- Ma JY, Yan HJ, Gu W : Association between *BIM* deletion polymorphism and clinical outcome of *EGFR*-mutated NSCLC patient with *EGFR*-TKI therapy : A meta-analysis. *J Cancer Res Ther* 11 : 397-402, 2015
- Huang WF, Liu AH, Zhao HJ, Dong HM, Liu LY, Cai SX : *BIM*

- gene polymorphism lowers the efficacy of EGFR-TKIs in advanced nonsmall cell lung cancer with sensitive EGFR mutations : a systematic review and meta-analysis. *Medicine (Baltimore)* 94 : e1263, 2015
12. Nie W, Tao X, Wei H, Chen WS, Li B : The BIM deletion polymorphism is a prognostic biomarker of EGFR-TKIs response in NSCLC : a systematic review and meta-analysis. *Oncotarget* 6 : 25696-25700, 2015
 13. Zou Q, Zhan P, Lv T, Song Y : The relationship between BIM deletion polymorphism and clinical significance of epidermal growth factor receptor-mutated non-small cell lung cancer patients with epidermal growth factor receptor-tyrosine kinase inhibitor therapy : a meta-analysis. *Transl Lung Cancer Res* 4 : 792-796, 2015
 14. Sato A : Vorinostat approved in Japan for treatment of cutaneous T-cell lymphoma : status and prospects. *Onco Targets Ther* 5 : 67-76, 2012
 15. Nakagawa T, Takeuchi S, Yamada T, Ebi H, Sano T, Nanjo S, Ishikawa D, Sato M, Hasegawa Y, Sekido Y, Yano S : EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition. *Cancer Res* 73 : 2428-2434, 2013
 16. Han JY, Lee SH, Lee GK, Yun T, Lee YJ, Hwang KH, Kim JY, Kim HT : Phase I/II study of gefitinib (Iressa[®]) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer. *Cancer Chemother Pharmacol* 75 : 475-83, 2015
 17. Reguart N, Rosell R, Cardenal F, Cardona AF, Isla D, Palmero R, Moran T, Rofco C, Pallarès MC, Insa A, Carcereny E, Majem M, De Castro J, Queralt C, Molina MA, Taron M : Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression. *Lung Cancer* 84 : 161-7, 2014